com_NN
Sales_NN
and_PHC
marketing_GER
Key_NN
products_NN
Key_NN
products_NN
:_:
Cardiovascular_NN
1_CD
Atacand_NN
candesartan_NN
cilexetil_NN
angiotensin_NN
II_NN
antagonist_NN
for_PIN
hypertension_NN
2_CD
Crestor_NN
rosuvastatin_NN
calcium_NN
HMG-CoA_NN
reductase_NN
inhibitor_NN
statin_NN
for_PIN
dyslipidemia_NN
Exanta_NN
ximelagatran_JJ
oral_JJ
direct_JJ
thrombin_NN
inhibitor_NN
for_PIN
prevention_NOMZ
of_PIN
thrombosis_NN
in_PIN
association_NOMZ
with_PIN
major_JJ
orthopaedic_JJ
surgery_NN
Plendil_NN
felodipine_NN
calcium_NN
antagonist_NN
for_PIN
hypertension_NN
and_PHC
angina_NN
Seloken_NN
Toprol-XL_NN
metoprolol_NN
succinate_NN
beta_JJ
blocker_NN
for_PIN
hypertension_NN
,_,
angina_NN
,_,
heart_NN
failure_NN
and_CC
other_JJ
uses_NN
3_CD
Zestril_NN
lisinopril_NN
dihydrate_NN
angiotensin_NN
We_FPP1
aim_VPRT
to_TO
build_VB
on_PIN
our_FPP1
success_NN
In_PIN
the_DT
US_FPP1
,_,
we_FPP1
aim_VPRT
to_TO [SPIN]
effectively_RB
converting_VBG
enzyme_JJ
inhibitor_NN
for_PIN
hypertension_NN
,_,
heart_NN
failure_NN
and_CC
diabetic_JJ
nephropathy_NN
in_PIN
Europe_NN
and_PHC
Japan_NN
,_,
while_OSUB
manage_VB
the_DT
challenges_NN
of_PIN
the_DT
increasing_VBG
our_FPP1
strength_NN
in_PIN
changing_VBG
external_JJ
environment_NOMZ
,_,
Key_NN
products_NN
:_:
Gastrointestinal_JJ
emerging_VBG
markets_NN
,_,
such_JJ
as_IN
while_OSUB
making_VBG
the_DT
most_EMPH
of_PIN
the_DT
Losec_NN
Prilosec_NN
omeprazole_NN
proton_NN
pump_NN
inhibitor_NN
for_PIN
acid-related_JJ
diseases_NN
China_NN
and_PHC
Mexico_NN
._.
opportunities_NOMZ
presented_VBN [WZPAST]
by_PIN
the_DT
Nexium_NN
esomeprazole_NN
magnesium_NN
proton_NN
pump_NN
inhibitor_NN
for_PIN
acid-related_JJ
diseases_NN
Bruno_NN
Angelici_NN
,_,
growing_VBG
demand_NN
for_PIN
innovative_JJ
Executive_NN
Vice-President_NN
,_,
medicines_NN
._.
David_NN
Brennan_NN
,_,
Key_NN
products_NN
:_:
Infection_NOMZ
4_CD
Merrem_NN
Meronem_NN
meropenem_NN
ultra_NN
broad_JJ
Europe_NN
,_,
Japan_NN
,_,
Asia_NN
Pacific_NN
Executive_NN
Vice-President_NN
,_,
spectrum_NN
injectable_JJ
antibiotic_JJ
for_PIN
serious_JJ
and_CC
ROW_NN
North_NN
America_NN
bacterial_JJ
infection_NOMZ
Key_NN
products_NN
:_:
Neuroscience_NN
We_FPP1
combine_VPRT
our_FPP1
global_JJ
capabilities_NOMZ
Toprol-XL_JJ
and_CC
Crestor_NN
,_,
with_PIN
combined_VBN
Diprivan_NN
propofol_NN
intravenous_JJ
general_JJ
anesthetic_NN
for_PIN
induction_NOMZ
maintenance_NN
of_PIN
anaesthesia_NN
and_CC
with_PIN
high_JJ
quality_NOMZ
relationships_NN
in_PIN
our_FPP1
sales_NN
of_PIN
$_$
5.7_CD
billion_CD
,_,
continue_VPRT
to_TO
underpin_VB
sedation_NOMZ
of_PIN
intensive_JJ
care_NN
patients_NN
local_JJ
markets_NN
and_CC
focus_VB
on_PIN
responding_VBG
our_FPP1
sales_NN
performance_NN
in_PIN
this_DEMO
highly_AMP
Naropin_JJ
ropivacaine_NN
local_JJ
anesthetic_JJ
quickly_RB
and_PHC
effectively_RB
to_PIN
our_FPP1
customers_NN
competitive_JJ
market_NN
._.
for_PIN
surgical_JJ
anaesthesia_NN
and_CC
acute_JJ
pain_NN
management_NOMZ
changing_VBG [WZPRES]
needs_NN
._.
We_FPP1
sell_VPRT
mostly_RB
through_PIN
Seroquel_NN
quetiapine_NN
fumarate_NN
atypical_JJ
our_FPP1
own_JJ
local_JJ
marketing_GER
companies_NN
In_PIN
Europe_NN
,_,
pharmaceutical_JJ
cost_NN
control_NN
anti-psychotic_JJ
for_PIN
schizophrenia_NN
and_CC
other_JJ
and_CC
our_FPP1
products_NN
are_VPRT [PASS]
marketed_VBN
mainly_RB
pressure_NN
continues_VPRT
to_TO
restrict_VB
market_NN
psychotic_JJ
disorders_NN
Xylocaine_NN
lidocaine_NN
local_JJ
anesthetic_JJ
for_PIN
use_NN
to_PIN
physicians_NN
and_CC
other_JJ
healthcare_NN
growth_NN
,_,
which_WDT [SERE]
is_VPRT [SPAU]
still_RB
increasing_VBG
but_CC
at_PIN
a_DT
in_PIN
surgery_NN
and_PHC
dentistry_NN
professionals_NN
._.
Despite_PIN
this_DEMO
background_NN
,_,
our_FPP1
Zomig_NN
zolmitriptan_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
acute_JJ
sales_NN
growth_NN
outpaced_VBD
the_DT
overall_JJ
market_NN
,_,
migraine_NN
with_PIN
or_CC
without_PIN
aura_NN
Our_FPP1
medicines_NN
are_VPRT [PASS]
designed_VBN
to_TO
improve_VB
with_PIN
a_DT
strong_JJ
performance_NN
from_PIN
Crestor_NN
,_,
health_NN
and_PHC
quality_NOMZ
of_PIN
life_NN
._.
They_TPP3
bring_VPRT
other_JJ
Nexium_NN
,_,
Seroquel_NN
,_,
Arimidex_NN
and_PHC
Symbicort_NN
._.
Key_NN
products_NN
:_:
Oncology_NN
Arimidex_NN
anastrozole_NN
aromatase_NN
inhibitor_NN
benefits_NN
too_RB
._.
We_FPP1
also_RB
talk_VPRT
to_PIN
governments_NOMZ
This_DEMO
performance_NN
,_,
coupled_VBN [PASTP]
with_PIN
our_FPP1
for_PIN
breast_NN
cancer_NN
and_PHC
groups_NN
that_TSUB
buy_VPRT
healthcare_NN
,_,
such_JJ
as_IN
investment_NOMZ
in_PIN
Central_NN
and_PHC
Eastern_NN
Europe_NN
,_,
Casodex_NN
bicalutamide_NN
anti-androgen_NN
managed_VBD
care_NN
organizations_NOMZ
in_PIN
the_DT
US_FPP1
,_,
provides_VPRT
a_DT
solid_JJ
basis_NN
for_PIN
future_JJ
growth_NN
in_PIN
for_PIN
prostate_NN
cancer_NN
Faslodex_NN
fulvestrant_JJ
estrogen_NN
receptor_NN
about_IN
the_DT
economic_JJ
as_RB
well_RB
as_IN
the_DT
the_DT
region_NN
._.
Sales_NN
totalled_VBD
$_$
7.6_CD
billion_CD
in_PIN
2004_CD
antagonist_NN
with_PIN
no_SYNE
agonist_JJ
effects_NN
for_PIN
breast_NN
therapeutic_JJ
advantages_NN
of_PIN
our_FPP1
range_NN
._.
and_ANDC
AstraZeneca_NN
ranks_VPRT
fifth_JJ
in_PIN
Europe_NN
._.
cancer_NN
By_PIN
reducing_VBG
the_DT
incidence_NN
of_PIN
disease_NN
Iressa_NN
gefitinib_NN
signal_NN
transduction_NOMZ
inhibitor_NN
for_PIN
non-small_JJ
cell_NN
lung_NN
cancer_NN
or_CC
improving_VBG
the_DT
efficiency_NN
of_PIN
treatment_NOMZ
,_,
In_PIN
Japan_NN
,_,
AstraZeneca_NN
was_VBD [BEMA]
the_DT
second_JJ
Nolvadex_NN
tamoxifen_NN
citrate_VB
anti-oestrogen_JJ
our_FPP1
medicines_NN
help_VPRT
to_TO
relieve_VB
the_DT
growing_VBG
fastest_JJ
growing_VBG
pharmaceutical_JJ
company_NN
for_PIN
breast_NN
cancer_NN
pressure_NN
on_PIN
healthcare_NN
systems_NN
and_CC
in_PIN
2004_CD
._.
A_DT
strong_JJ
performance_NN
by_PIN
Zoladex_NN
goserelin_NN
acetate_NN
LHRH_NN
agonist_NN
for_PIN
prostate_NN
and_CC
pre-menopausal_JJ
breast_NN
cancer_NN
,_,
budgets_NN
._.
Arimidex_NN
,_,
Casodex_NN
,_,
Zoladex_NN
and_PHC
Iressa_NN
,_,
certain_JJ
benign_JJ
gynaecological_JJ
disorders_NN
and_CC
and_CC
good_JJ
growth_NN
for_PIN
Losec_NN
,_,
drove_VBD
sales_NN
assisted_VBD
reproduction_NOMZ
Success_NN
in_PIN
key_JJ
markets_NN
is_VPRT [BEMA]
a_DT
top_JJ
priority_NOMZ
._.
to_TO
$_$
1.4_CD
billion_CD
and_CC
we_FPP1
now_TIME
rank_VPRT
13th_JJ
by_PIN
We_FPP1
aim_VPRT
to_TO
build_VB
on_PIN
our_FPP1
leading_VBG
positions_NOMZ
sales_NN
in_PIN
Japan_NN
._.
Key_NN
products_NN
:_:
Respiratory_JJ
and_CC
Inflammation_NOMZ
in_PIN
major_JJ
markets_NN
,_,
especially_RB
the_DT
US_FPP1
,_,
Accolate_NN
zafirlukast_NN
oral_JJ
leukotriene_NN
receptor_NN
antagonist_NN
for_PIN
control_NN
of_PIN
asthma_NN
Japan_NN
and_PHC
Europe_NN
,_,
whilst_OSUB
increasing_VBG
our_FPP1
Overall_JJ
sales_NN
in_PIN
Asia_NN
Pacific_NN
grew_VBD
by_PIN
Oxis_NN
formoterol_NN
inhaled_VBD
fast_RB
onset_NN
long-acting_JJ
strength_NN
through_PIN
strategic_JJ
investment_NOMZ
in_PIN
an_DT
underlying_JJ
rate_NN
of_PIN
18_CD
%_NN
to_TO
$_$
1.2_CD
billion_CD
bronchodilator_NN
for_PIN
relief_NN
of_PIN
asthma_NN
symptoms_NN
the_DT
small_JJ
but_CC
fast-growing_JJ
markets_NN
of_PIN
the_DT
and_CC
the_DT
region_NN
represents_VPRT
an_DT
area_NN
of_PIN
Pulmicort_NN
budesonide_NN
inhaled_VBD
anti-inflammatory_JJ
for_PIN
asthma_NN
control_NN
future_JJ
the_DT
emerging_VBG
economies_NN
,_,
high_JJ
growth_NN
potential_NN
._.
In_PIN
China_NN
,_,
we_FPP1
are_VPRT
Rhinocort_NN
budesonide_NN
topical_JJ
nasal_JJ
such_JJ
as_IN
China_NN
and_PHC
Mexico_NN
._.
now_DPAR
the_DT
largest_JJ
multi-national_JJ
prescription_NOMZ
anti-inflammatory_JJ
for_PIN
control_NN
of_PIN
rhinitis_NN
drug_NN
company_NN
and_CC
one_CD
of_PIN
the_DT
fastest_JJ
Symbicort_NN
budesonide_NN
formoterol_NN
inhaled_VBD
combination_NOMZ
of_PIN
anti-inflammatory_JJ
and_PHC
fast_JJ
onset_NN
Our_FPP1
US_FPP1
sales_NN
of_PIN
$_$
9.6_CD
billion_CD
in_PIN
2004_CD
reflect_VPRT [PRIV]
growing_VBG
pharmaceutical_JJ
companies_NN
._.
long-acting_JJ
bronchodilator_NN
in_PIN
a_DT
single_JJ
inhaler_NN
our_FPP1
commitment_NOMZ
to_TO
driving_VBG
growth_NN
in_PIN
this_DEMP
,_,
the_DT
worlds_NN
largest_JJ
pharmaceutical_JJ
market_NN
._.
Elsewhere_RB
,_,
good_JJ
growth_NN
in_PIN
Latin_NN
America_NN
1_CD
Licensed_VBN
from_PIN
Takeda_NN
Chemical_NN
Industries_NN
Ltd._NN
._.
With_PIN
a_DT
5_CD
%_NN
market_NN
share_NN
,_,
AstraZeneca_NN
is_VPRT [BEMA]
27_CD
%_NN
and_CC
a_DT
$_$
40_CD
million_CD
investment_NOMZ
in_PIN
new_JJ
2_CD
Licensed_VBN
from_PIN
Shionogi_NN
&_CC
Co._NN
._.
Ltd._NN
3_CD
the_DT
fifth_JJ
largest_JJ
pharmaceutical_JJ
company_NN
,_,
manufacturing_VBG [PRESP]
in_PIN
Egypt_NN
further_JJ
strengthens_VPRT
Licensed_VBN
from_PIN
Merck_NN
&_CC
Co._NN
._.
Inc._NN
4_CD
Licensed_VBN
from_PIN
Sumitomo_NN
Pharmaceuticals_NN
Co._NN
._.
Ltd._NN
by_PIN
sales_NN
in_PIN
the_DT
US_FPP1
._.
Nexium_NN
,_,
Seroquel_NN
,_,
our_FPP1
platform_NN
for_PIN
regional_JJ
expansion_NN
._.
